GlassScriptPhysician profile
Edward Wan-Jae Lee
NPI 1487866588
$8,306.65
in general payments reported to CMS, 2019-2025
28 companies · $2,026 in 2025
The $2,026 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,393 · 2020: $492 · 2021: $880 · 2022: $954 · 2023: $855 · 2024: $1,706 · 2025: $2,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,586.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $1,315.77 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Abbvie INC. | $966.04 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $904.78 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Novartis Pharmaceuticals Corporation | $668.54 | 2019-2023 | |
| Horizon Therapeutics Plc | $534.12 | 2021-2023 | Tepezza |
| Amgen INC. | $509.86 | 2024-2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $500.60 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $483.32 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $456.22 | 2019-2025 | Rocklatan, Argos, Eysuvis |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $435.57 | 2019-2021 | |
| Allergan, INC. | $343.72 | 2019-2022 | |
| Shire North American Group INC | $184.23 | 2019 | |
| Eyevance Pharmaceuticals LLC | $178.40 | 2019-2023 | Tobradex St |
| Sun Pharmaceutical Industries INC. | $171.28 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $144.86 | 2022-2025 | Tyrvaya |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $83.02 | 2024-2025 | Oxervate |
| Nova Eye, INC. | $75.24 | 2025 | |
| Alimera Sciences, INC. | $54.29 | 2019 | |
| Harrow Eye, LLC | $49.70 | 2025 | Vevye |
| Rxsight INC | $43.17 | 2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
| Thea Pharma INC. | $41.53 | 2022-2024 | Iyuzeh |
| Akorn Operating Company LLC | $35.64 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $26.74 | 2022 | |
| Genentech USA, INC. | $23.88 | 2022 | |
| Topcon Healthcare Solutions, INC. | $19.51 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| New World Medical,INC. | $19.32 | 2020 | |
| Kala Pharmaceuticals, INC. | $17.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.